Engineered Dendritic Cells Boost Cancer Immunotherapy

In Body Dendritic Cell Engineering Advances Immunotherapy Technology Integrating new knowledge of dc biology and advancements in cell engineering, we provide a blueprint for the rational design of optimized dc vaccines for personalized cancer medicine. Epfl scientists boost immunotherapy with engineered dendritic cells that capture tumor evs and activate t cells inside the patient’s body. learn more.

Engineered Dendritic Cells Harness Tumor Evs To Boost Cancer The ability of dendritic cells (dcs) to provide all three signals required for t cell activation makes them an ideal cancer vaccine platform. several strategies have been developed to enhance and control antigen presentation, costimulation, and cytokine production. Central to this emerging approach are dendritic cells (dcs), which boast a remarkable ability for antigen presentation. this ability is being leveraged to modulate t and b cell immunity, offering a groundbreaking strategy for tackling cancer. Being key mediators of cd8 t cell responses, dendritic cells have tremendous potential for cancer immunotherapy. to date however, the performance of dc based therapies has been limited. Epfl researchers have successfully engineered cells of the immune system to more effectively recognize cancer cells. the work, covered in two papers, turns the previously lab based method into a full blown immunotherapy strategy.

Engineered Dendritic Cells Boost Cancer Immunotherapy Being key mediators of cd8 t cell responses, dendritic cells have tremendous potential for cancer immunotherapy. to date however, the performance of dc based therapies has been limited. Epfl researchers have successfully engineered cells of the immune system to more effectively recognize cancer cells. the work, covered in two papers, turns the previously lab based method into a full blown immunotherapy strategy. Engineered dendritic cells capture tumor evs, enhancing antigen presentation and t cell activation to boost cancer immunotherapy in preclinical models. Researchers at the ecole polytechnique fédérale de lausanne (epfl), led by michele de palma, phd, have developed two bioengineering strategies to exploit evs and enhance dendritic‑cell immunotherapy. Dc based cancer immunotherapy harnesses dcs’ unique capacity to bridge innate and adaptive immunity, thereby cyclically priming tumor specific effector t cells and stimulating cancer cell cytotoxicity. Engineered dendritic cells use extracellular vesicles and exosomes from tumors to enhance antigen presentation and boost immune responses against resistant cancers.